SENSCISTM

Safety and Efficacy of Nintedanib in Systemic SClerosIS

Clinical Research Study for
Scleroderma with Interstitial Lung
Disease (lung scarring)


We all have reasons to keep fighting Scleroderma Lung Disease.


If you have been diagnosed with Systemic Sclerosis with Interstitial Lung Disease (SSc-ILD), you could be eligible to participate in SENSCISTM, a clinical research study of an investigational drug for SSc-ILD called nintedanib.

Nintedanib is an oral drug that has been approved in the United States and Europe for the treatment of idiopathic pulmonary fibrosis, which is a disease similar to SSc-ILD. Nintedanib has not been approved for the treatment of SSc-ILD.

To pre-qualify for this study, you must:

Additional research study criteria will be evaluated by a study doctor to determine if you qualify. All study-related visits, tests, and drugs will be provided at no cost. In addition, reimbursement for study-related time and travel may be provided.

See If You Qualify & Find a Study Site:

Are you willing to answer a few questions to see if you may be eligible to participate in the SENSCISTM clinical research study? If you’re interested in learning more, please fill out the form below to see if you may qualify.

(*All Questions are Required)

*Are you 18 or older?



*Have you been diagnosed with Systemic Sclerosis within the past 5 years?



*Have you been treated with nintedanib or pirfenidone?



*Have you suffered a stroke within the last year?



*Please enter your zip code to locate the study site nearest to you: